Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Rivastigmine Tartrate Articles

Focus On Exelon For Alzheimer's Disease

14 August 1997

1st Approval For Novartis' Exelon; 2nd For Revasc

7 August 1997

Novartis Unveils Strong Product Pipeline

1 July 1997

Novartis To File Exelon Worldwide This Month

20 March 1997

Eisai's Aricept Available In USA, Its First Market

27 January 1997

No Hidden Surprises From US FTC For Birth Of Novartis

6 January 1997

Sandoz' Alzheimer's Drug; International Data Revealed

2 December 1996

Galanthamine Enters Ph III In USA For Alzheimer's

28 October 1996

Europe Stock Comment

5 August 1996

First Efficacy Data With Sandoz' Exelon

5 August 1996

Novartis Pipeline: A Good Fit But Cuts Are Expected

18 March 1996

Novartis Pipeline: A Good Fit But Cuts Are Expected

18 March 1996

FDA Panel Backs Cellcept For Acute Rejection

10 April 1995

SANDIMMUN SET FOR DECLINE, SAYS ANALYST

27 June 1994

Showing 101-114 of 114 articles

Go to beginningPrevious
  • 1
  • 2
NextGo to end
  • Hot Topics
  • Most Read
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS